- Home
- BEEM vs IGC Comparison
BEEM vs IGC Comparison
Compare BEEM & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEEM
- IGC
- Stock Information
- Founded
- BEEM 2006
- IGC 2005
- Country
- BEEM United States
- IGC United States
- Employees
- BEEM N/A
- IGC N/A
- Industry
- BEEM Semiconductors
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- BEEM Technology
- IGC Health Care
- Exchange
- BEEM Nasdaq
- IGC Nasdaq
- Market Cap
- BEEM 21.7M
- IGC 20.2M
- IPO Year
- BEEM N/A
- IGC N/A
- Fundamental
- Price
- BEEM $1.61
- IGC $0.31
- Analyst Decision
- BEEM Strong Buy
- IGC Strong Buy
- Analyst Count
- BEEM 4
- IGC 2
- Target Price
- BEEM $5.33
- IGC $3.88
- AVG Volume (30 Days)
- BEEM 142.0K
- IGC 204.3K
- Earning Date
- BEEM 05-15-2025
- IGC 06-23-2025
- Dividend Yield
- BEEM N/A
- IGC N/A
- EPS Growth
- BEEM N/A
- IGC N/A
- EPS
- BEEM N/A
- IGC N/A
- Revenue
- BEEM $41,099,000.00
- IGC $1,236,000.00
- Revenue This Year
- BEEM $27.41
- IGC N/A
- Revenue Next Year
- BEEM $58.00
- IGC $16.45
- P/E Ratio
- BEEM N/A
- IGC N/A
- Revenue Growth
- BEEM N/A
- IGC 1.65
- 52 Week Low
- BEEM $1.33
- IGC $0.25
- 52 Week High
- BEEM $7.68
- IGC $0.55
- Technical
- Relative Strength Index (RSI)
- BEEM 45.77
- IGC 52.27
- Support Level
- BEEM $1.65
- IGC $0.28
- Resistance Level
- BEEM $1.87
- IGC $0.32
- Average True Range (ATR)
- BEEM 0.14
- IGC 0.02
- MACD
- BEEM 0.00
- IGC 0.00
- Stochastic Oscillator
- BEEM 14.04
- IGC 40.67
About BEEM Beam Global
Beam Global produces sustainable technology for electric vehicle (EV) charging, outdoor media, and energy security, without the construction, disruption, and costs of grid-tied solutions. Its products are founded upon its patented EV ARC and Solar Treelines and include BeamTrak patented solar tracking, and ARC Technology energy storage, along with EV charging, outdoor media, and disaster preparedness packages. From start to finish, the company develops, patents, designs, engineers, and manufactures renewably energized products that help the environment, empower communities, and keep people moving.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.